ArticleDrug design, development and therapy2026
Sophocarpine Alleviates Airway Epithelial Cell Inflammation in Asthma via Modulating the Cytokine- Cytokine Receptor and JAK2/STAT3 Signaling Pathways.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Asthma is a complex, heterogeneous, and inflammatory disease with an increasing incidence worldwide. This study aimed to investigate the therapeutic mechanisms of sophocarpine in asthma systematically. Methods: A house dust mite (HDM)-induced mouse and cell model was built. The effects and mechanisms of sophocarpine on asthma were evaluated in vivo and in vitro. Results: In the mouse model, sophocarpine treatment reduced airway pathological damage, mucus secretion, levels of interleukin (IL)-4, IL-5, IL-17, immunoglobulin E (IgE), and splenic index, as well as eosinophil accumulation. Network pharmacology studies revealed that sophocarpine may target TLR4, STAT3, and TNF, and regulates the JAK-STAT, and Viral protein interaction with cytokine and cytokine receptor signaling pathway et al. Docking results showed that the binding energy of sophocarpine to major targets varied from -7.55 to -5.22 kcal/mol. Transcriptome analysis identified 436 DEGs, which were enriched in pathways consistent with the network pharmacology, such as the JAK-STAT signaling pathway. We further confirmed that sophocarpine downregulated the mRNA expression levels of CCL5, CCL7, CCL12, CXCL1, CXCL2, CXCL3, CCR2, CXCR2, CXCR3, JAK2, STAT3, and c-MYC, and protein expression of CXCR2, JAK2, STAT3, and c-MYC in the mouse model. Sophocarpine also inhibited HDM-induced BEAS-2B cell viability decrease, cell apoptosis, and ROS overproduction, which was associated with modulation of the cytokine-cytokine receptor and JAK-STAT signaling pathways. Further, similar to sophocarpine, STAT3 inhibitors and siRNA effectively reduced the levels of STAT3, MYC, and CXCR2. Conclusion: These results indicate that sophocarpine effectively inhibits HDM-induced airway epithelial cell inflammation through regulating cytokine-cytokine receptor and JAK2/STAT3 signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.